BCL2 and ovarian carcinoma: In conclusion, our study identifies a novel molecular mechanism for E2F1, whereby it targets miR-519d to upregulate RhoC, Bcl-2, cyclin D1, survivin, MMP2, MMP9, STAT3 and HuR expression, promoting tumorigenesis and progression in ovarian carcinoma.